{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:32:07Z","timestamp":1791977527695,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Acute Heart Failure (AHF) presents as a serious pathophysiological disease with significant morbidity and mortality rates, requiring immediate medical intervention. Traditional treatment involves diuretics and vasodilators, but a subset of patients develop resistance due to acute cardiorenal syndrome. Dapagliflozin, categorized as a sodium-glucose cotransporter-2 inhibitor (SGLT2i), has emerged as a promising therapy for AHF, demonstrating substantial benefits in reducing both mortality and morbidity among patients. The purpose of this meta-analysis and systematic review is to determine dapagliflozin\u2019s safety and efficacy in AHF patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In accordance with PRISMA guidelines, we conducted a systematic search across several databases (PubMed, Science Direct, and Cochrane Library) up to June 2024 to identify randomized controlled trials (RCTs) that compared dapagliflozin with control treatments in patients with AHF. Key outcomes of interest included In-Hospital Cardiovascular mortality rates, duration of hospitalization, and instances of in-hospital worsening. Data extraction and quality assessment adhered to established protocols and the results were evaluated using Review Manager (RevMan Version 5.4.1) The assessment of bias risk follows the principles established in the Cochrane Handbook for Systematic Reviews and Meta-Analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Five RCTs comprising 912 patients met the inclusion criteria. Dapagliflozin significantly reduced In-Hospital Cardiovascular mortality (RR 0.56, 95% CI 0.36\u20130.88, <jats:italic>p<\/jats:italic>\u2009=\u20090.01, I\u00b2=26%) and 30-day hospital readmissions (RR 0.73, CI 0.54\u20130.99, <jats:italic>p<\/jats:italic>\u2009=\u20090.05, I\u00b2=7%). However, dapagliflozin did not significantly affect the length of hospital stay (MD -0.11, CI -0.73-0.51, <jats:italic>p<\/jats:italic>\u2009=\u20090.72, I\u00b2=60%) or the incidence of hypotension (RR 0.82, CI 0.36\u20131.84, <jats:italic>p<\/jats:italic>\u2009=\u20090.63, I\u00b2=0%). A significant weight change was observed (MD 0.93, CI 0.03\u20131.83, <jats:italic>p<\/jats:italic>\u2009=\u20090.04, I\u00b2=95%), which was resolved upon sensitivity analysis (MD 1.34, CI 1.02\u20131.66, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001, I\u00b2=0%). No significant effects were found for worsening renal failure or changes in GFR in this study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Dapagliflozin appears to be beneficial in reducing In-Hospital Cardiovascular mortality and 30-day hospital readmissions in AHF patients. Although it demonstrates potential, additional research is needed to establish its significance in AHF management. Further investigation with larger sample sizes, different doses, and comprehensive safety and cost-effectiveness is imperative to thoroughly evaluate the safety and clinical efficacy of Dapagliflozin, underscoring the necessity for additional data to substantiate its role in managing patients with AHF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Clinical trial number<\/jats:title>\n                <jats:p>Not applicable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-024-04412-x","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T02:51:33Z","timestamp":1735354293000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Dapagliflozin in acute heart failure management: a systematic review and meta-analysis of safety and effectiveness"],"prefix":"10.1186","volume":"24","author":[{"given":"Adarsh","family":"Raja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mata-e-Alla","family":"Dogar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3158-534X","authenticated-orcid":false,"given":"Sandesh","family":"Raja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hamza","family":"Shuja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafin Bin","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muskan","family":"Khelani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urooj","family":"Fatima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiman","family":"Soomro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayesha","family":"Habiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iqra","family":"Mustafa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakhshan","family":"Zulfiqar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Sohaib","family":"Asghar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"4412_CR1","doi-asserted-by":"publisher","unstructured":"Kumar DA, Muneer DK, Qureshi DN. Relationship between high sensitivity troponin I and clinical outcomes in non\u2013acute coronary syndrome (non-ACS) acute heart failure patients \u2013 a one-year follow-up study. Indian Heart J. 2024;76(2):139\u201345. https:\/\/doi.org\/10.1016\/J.IHJ.2024.04.003","DOI":"10.1016\/J.IHJ.2024.04.003"},{"key":"4412_CR2","doi-asserted-by":"publisher","unstructured":"Cosentino N, Campodonico J. Acute heart failure: diagnosis first and then treatment. Int J Cardiol. Oct. 2018;269:224\u20135. https:\/\/doi.org\/10.1016\/j.ijcard.2018.07.032.","DOI":"10.1016\/j.ijcard.2018.07.032"},{"issue":"1","key":"4412_CR3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.5505\/KJMS.2022.64426","volume":"12","author":"F K\u00f6ksal","year":"2022","unstructured":"K\u00f6ksal F, Aldemir M, Levent F, Emren SV, Nazl\u0131 C. The Effect of the practical treatments for Acute Heart failure on In-Hospital Cardiovascular mortality: a real-world study. Kafkas J Med Sci. 2022;12(1):37\u201343. https:\/\/doi.org\/10.5505\/KJMS.2022.64426.","journal-title":"Kafkas J Med Sci"},{"key":"4412_CR4","doi-asserted-by":"publisher","unstructured":"Kurmani S, Squire I. Acute Heart Failure: Definition, Classification and Epidemiology. Curr Heart Fail Rep. 2017;14(5):385\u201392. https:\/\/doi.org\/10.1007\/S11897-017-0351-Y","DOI":"10.1007\/S11897-017-0351-Y"},{"key":"4412_CR5","doi-asserted-by":"publisher","unstructured":"Di Somma S, Magrini L. Drug Therapy for Acute Heart Failure. Revista Espa\u00f1ola de Cardiolog\u00eda (English Edition). 2015;68(8):706\u201313. https:\/\/doi.org\/10.1016\/J.REC.2015.02.019","DOI":"10.1016\/J.REC.2015.02.019"},{"key":"4412_CR6","doi-asserted-by":"publisher","unstructured":"Funahashi Y, Chowdhury S, Eiwaz MB, Hutchens MP. Acute Cardiorenal Syndrome: Models and Heart-Kidney Connectors. Nephron. 2020;144(12):629\u201333. https:\/\/doi.org\/10.1159\/000509353","DOI":"10.1159\/000509353"},{"key":"4412_CR7","doi-asserted-by":"publisher","unstructured":"Elnaem MH, Mansour NO, Nahas AF, Baraka MA, Elkalmi R, Cheema E, \u2009Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations,. 2020. https:\/\/doi.org\/10.2147\/IJGM.S285191","DOI":"10.2147\/IJGM.S285191"},{"key":"4412_CR8","doi-asserted-by":"publisher","unstructured":"Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, B\u011blohl\u00e1vek J, B\u00f6hm M, Chiang CE, Chopra VK, de Boer RA, Desai AS. Effect of dapagliflozin on worsening heart failure and cardiovascular death in patients with heart failure with and without diabetes. Jama. 2020;323(14):1353\u201368. https:\/\/doi.org\/10.1001\/jama.2020.1906","DOI":"10.1001\/jama.2020.1906"},{"key":"4412_CR9","doi-asserted-by":"publisher","unstructured":"Page MJ. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Rev. 2021;10. https:\/\/doi.org\/10.1186\/S13643-021-01626-4","DOI":"10.1186\/S13643-021-01626-4"},{"key":"4412_CR10","doi-asserted-by":"publisher","unstructured":"Sterne JAC. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366. https:\/\/doi.org\/10.1136\/BMJ.L4898","DOI":"10.1136\/BMJ.L4898"},{"key":"4412_CR11","doi-asserted-by":"publisher","unstructured":"Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. Bmj. 2003;327(7414):557\u201360. https:\/\/doi.org\/10.1136\/BMJ.327.7414.557","DOI":"10.1136\/BMJ.327.7414.557"},{"key":"4412_CR12","doi-asserted-by":"publisher","unstructured":"Cox ZL, Collins SP, Hernandez GA, McRae III AT, Davidson BT, Adams K, et al. Efficacy and safety of dapagliflozin in patients with acute heart failure. J Am Coll Cardiol. 2024;83(14):1295\u2013306. https:\/\/doi.org\/10.1016\/J.JACC.2024.02.009","DOI":"10.1016\/J.JACC.2024.02.009"},{"key":"4412_CR13","doi-asserted-by":"publisher","unstructured":"Emara AN, Wadie M, Mansour NO, Shams ME. The clinical outcomes of dapagliflozin in patients with acute heart failure: a randomized controlled trial (DAPA-RESPONSE-AHF). Eur J Pharmacol. 2023;961:176179. https:\/\/doi.org\/10.1016\/J.EJPHAR.2023.176179","DOI":"10.1016\/J.EJPHAR.2023.176179"},{"key":"4412_CR14","doi-asserted-by":"publisher","unstructured":"Charaya KV, Schekochikhin DY, Nikiforova TV, Dimchishina AS, Soboleva TV, Shkliarov AM, et al. The use of Dapagliflozin in Acute Decompensated Heart Failure: Results of the Randomized Study. Kardiologiia. 2023;63(8):11\u20138. https:\/\/doi.org\/10.18087\/cardio.2023.8.n2221","DOI":"10.18087\/cardio.2023.8.n2221"},{"key":"4412_CR15","doi-asserted-by":"publisher","unstructured":"Charaya K, Shchekochikhin D, Agadzhanyan A, Vashkevich M, Chashkina M, et al. Impact of dapagliflozin treatment on serum sodium concentrations in acute heart failure. Cardiorenal Med. 2023;13(1):101\u20138. https:\/\/doi.org\/10.1159\/000529614","DOI":"10.1159\/000529614"},{"key":"4412_CR16","doi-asserted-by":"publisher","unstructured":"Charaya K, Shchekochikhin D, Andreev D, Dyachuk I, Tarasenko S, Poltavskaya M, et al. Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study. Open Heart. 2022;9(1):e001936. https:\/\/doi.org\/10.1136\/OPENHRT-2021-001936","DOI":"10.1136\/OPENHRT-2021-001936"},{"key":"4412_CR17","doi-asserted-by":"publisher","unstructured":"Ponikowski P. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975. https:\/\/doi.org\/10.1002\/EJHF.592","DOI":"10.1002\/EJHF.592"},{"key":"4412_CR18","doi-asserted-by":"publisher","unstructured":"Coiro S, Girerd N, McMurray JJ, Pitt B, Swedberg K, van Veldhuisen DJ, et al. Diuretic therapy as prognostic enrichment factor for clinical trials in patients with heart failure with reduced ejection fraction. Clin Res Cardiol. 2021;110(8):1308\u201320. https:\/\/doi.org\/10.1007\/S00392-021-01851-W","DOI":"10.1007\/S00392-021-01851-W"},{"key":"4412_CR19","doi-asserted-by":"publisher","unstructured":"Holt DB, Pang PS. Vasodilator therapies in the treatment of acute heart failure. Curr Heart Fail Rep. 2019;16:32\u2013l7. https:\/\/doi.org\/10.1007\/S11897-019-0421-4\/METRICS","DOI":"10.1007\/S11897-019-0421-4\/METRICS"},{"key":"4412_CR20","doi-asserted-by":"publisher","unstructured":"Thadani U. Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance. Am J Cardiovasc Drugs. 2014;14:287\u2013301. https:\/\/doi.org\/10.1007\/S40256-014-0072-5\/METRICS","DOI":"10.1007\/S40256-014-0072-5\/METRICS"},{"key":"4412_CR21","unstructured":"Cardiovascular Pharmacology Concepts. Accessed: Jun. 30, 2024. [Online]. Available: https:\/\/cvpharmacology.com\/cardioinhibitory\/cardioinhibitory"},{"key":"4412_CR22","doi-asserted-by":"publisher","unstructured":"Mos L, Plett G, Degano C. Antihypertensive therapy in athletes. 2022:207\u2013223. https:\/\/doi.org\/10.1007\/978-3-031-07958-0_15","DOI":"10.1007\/978-3-031-07958-0_15"},{"key":"4412_CR23","doi-asserted-by":"publisher","unstructured":"Albarr\u00e1n OG, Ampudia-Blasco FJ. Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes. Medicina Clinica. 2013;141:36\u201343. https:\/\/doi.org\/10.1016\/S0025-7753(13)70062-9","DOI":"10.1016\/S0025-7753(13)70062-9"},{"key":"4412_CR24","doi-asserted-by":"publisher","unstructured":"Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG Outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59:1333\u20139. https:\/\/doi.org\/10.1007\/S00125-016-3956-X","DOI":"10.1007\/S00125-016-3956-X"},{"key":"4412_CR25","doi-asserted-by":"publisher","unstructured":"Bolinder J, Ljunggren \u00d6, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. The Journal of Clinical Endocrinology \u2013 Metabolism. 2012;97(3):1020\u201331. https:\/\/doi.org\/10.1210\/JC.2011-2260","DOI":"10.1210\/JC.2011-2260"},{"key":"4412_CR26","doi-asserted-by":"publisher","unstructured":"Lytvyn Y, Bjornstad P, Udell JA, Lovshin JA, Cherney DZ. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136(17):1643\u201358. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.117.030012","DOI":"10.1161\/CIRCULATIONAHA.117.030012"},{"key":"4412_CR27","doi-asserted-by":"publisher","unstructured":"Verma S, McMurray JJ. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review. Diabetologia. 2018;61:2108\u201317. https:\/\/doi.org\/10.1007\/S00125-018-4670-7","DOI":"10.1007\/S00125-018-4670-7"},{"key":"4412_CR28","doi-asserted-by":"publisher","unstructured":"Desai AS. Effect of dapagliflozin on cause-specific in-hospital cardiovascular mortality in patients with heart failure across the spectrum of ejection fraction: a participant-level pooled analysis of DAPA-HF and DELIVER. JAMA Cardiol. 2022;7(12):1227\u20131234. https:\/\/doi.org\/10.1001\/JAMACARDIO.2022.3736","DOI":"10.1001\/JAMACARDIO.2022.3736"},{"key":"4412_CR29","doi-asserted-by":"publisher","unstructured":"Crea F. A focus on three hot topics: atrial fibrillation, obesity, and climate change. Eur Heart J. 2024;45(24):2105\u20138. https:\/\/doi.org\/10.1093\/EURHEARTJ\/EHAE380","DOI":"10.1093\/EURHEARTJ\/EHAE380"},{"key":"4412_CR30","doi-asserted-by":"publisher","unstructured":"Kato ET, Effect of dapagliflozin on heart failure and in-hospital cardiovascular mortality in Type 2 diabetes mllitus. circulation. 2019;139(22):2528\u20132536. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.040130","DOI":"10.1161\/CIRCULATIONAHA.119.040130"},{"key":"4412_CR31","doi-asserted-by":"publisher","unstructured":"Zhai M, Du X, Liu C, Xu H. The effects of dapagliflozin in patients with heart failure complicated with type 2 diabetes: a meta-analysis of placebo-controlled randomized trials. Front clin diabetes healthc. 2021;2:703937. https:\/\/doi.org\/10.3389\/FCDHC.2021.703937","DOI":"10.3389\/FCDHC.2021.703937"},{"key":"4412_CR32","doi-asserted-by":"publisher","unstructured":"Mizobuchi S, Saito Y, Miyagawa M, Koyama Y, Fujito H, Kojima K, et al. Early initiation of dapagliflozin during hospitalization for acute heart failure is associated with a shorter hospital stay. Intern Med. 2023;62(21):3107\u201317. https:\/\/doi.org\/10.2169\/INTERNALMEDICINE.1215-22","DOI":"10.2169\/INTERNALMEDICINE.1215-22"},{"key":"4412_CR33","doi-asserted-by":"publisher","unstructured":"Jhund PS, Ponikowski P, Docherty KF, Gasparyan SB, B\u00f6hm M, Chiang CE, et al. Dapagliflozin and recurrent heart failure hospitalizations in heart failure with reduced ejection fraction: an analysis of DAPA-HF. Circulation. 2021;143(20):1962\u201372. https:\/\/doi.org\/10.1056\/NEJMOA1812389https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.053659.","DOI":"10.1056\/NEJMOA1812389"},{"key":"4412_CR34","doi-asserted-by":"publisher","unstructured":"Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347\u201357. https:\/\/doi.org\/10.1056\/NEJMOA1812389","DOI":"10.1056\/NEJMOA1812389"},{"key":"4412_CR35","doi-asserted-by":"publisher","unstructured":"Solomon SD, McMurray JJ, Claggett B, de Boer RA, DeMets D, Hernandez AF, Inzucchi SE, Kosiborod MN, Lam CS, Martinez F, Shah SJ. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089\u201398. https:\/\/doi.org\/10.1056\/NEJMOA2206286","DOI":"10.1056\/NEJMOA2206286"},{"key":"4412_CR36","doi-asserted-by":"publisher","unstructured":"Ali AE, Mazroua MS, ElSaban M, Najam N, Kothari AS, Mansoor T. Effect of dapagliflozin in patients with heart failure: a systematic review and meta-analysis. Glob Heart. 2023;18:45. https:\/\/doi.org\/10.5334\/GH.1258","DOI":"10.5334\/GH.1258"},{"key":"4412_CR37","doi-asserted-by":"publisher","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, K\u00f8ber L, Kosiborod MN, Martinez FA, Ponikowski P, Sabatine MS, Anand IS, B\u011blohl\u00e1vek J, B\u00f6hm M. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995\u20132008. https:\/\/doi.org\/10.1056\/NEJMOA1911303","DOI":"10.1056\/NEJMOA1911303"},{"key":"4412_CR38","doi-asserted-by":"publisher","unstructured":"Chatur S, Vaduganathan M, Claggett BL, Mc Causland FR, Desai AS, Jhund PS, et al. Dapagliflozin in patients with heart failure and deterioration in renal function. J Am Coll Cardiol. 2023;82(19):1854\u201363. https:\/\/doi.org\/10.1016\/J.JACC.2023.08.026","DOI":"10.1016\/J.JACC.2023.08.026"},{"key":"4412_CR39","doi-asserted-by":"publisher","unstructured":"Alanazi WA, Alharbi T, El-Nagar DM, Albogami AM, Alswayyed M. Dapagliflozin mitigates hypotension in lipopolysaccharide-induced acute inflammation independent of glycemia level. Pharmaceutics. 2023;15(6):1683. https:\/\/doi.org\/10.3390\/PHARMACEUTICS15061683\/S110.3390\/PHARMACEUTICS15061683\/S1","DOI":"10.3390\/PHARMACEUTICS15061683\/S1"},{"key":"4412_CR40","doi-asserted-by":"publisher","unstructured":"Rong X, Li X, Gou Q, Liu K, Chen X. Risk of orthostatic hypotension associated with sodium-glucose cotransporter-2 inhibitor treatment: a meta-analysis of randomized controlled trials. Diab Vasc Dis Res. 2020;17:5. https:\/\/doi.org\/10.1177\/1479164120953625","DOI":"10.1177\/1479164120953625"},{"key":"4412_CR41","unstructured":"FORXIGA\u00ae (dapagliflozin) Therapy in Heart Failure with Reduced Ejection Fraction (HFrEF) 1, 2021. [Online]. Available: www.azinfo.ca\/forxiga\/pm367"},{"key":"4412_CR42","doi-asserted-by":"publisher","unstructured":"Tikkanen I. Empagliflozin reduces blood pressure in patients with type 2 diabetes and hypertension. Diabetes Care. 2015;38(3):420\u2013428. https:\/\/doi.org\/10.2337\/DC14-1096","DOI":"10.2337\/DC14-1096"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04412-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-024-04412-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-024-04412-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T03:02:39Z","timestamp":1735354959000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-024-04412-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["4412"],"URL":"https:\/\/doi.org\/10.1186\/s12872-024-04412-x","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human ethics and consent to participate approval"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"749"}}